



Comment on “Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story”

Dear Editor, we would like to share ideas on the publication “Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story [1].” Tsilingiris et al. noted that “besides, with the issue of the potential necessity of additional boosters or even of repeat vaccinations on an annual basis still remaining open, further reasons for debate on the subject of VITT/TTS management are bound to emerge. [1].” We agree that vaccine induced thrombotic thrombocytopenia is a possible adverse reaction to COVID-19 vaccine. Tsilingiris et al. mentioned for several possible underlying mechanism of the problem including autoantibodies, megakaryocytes entry, direct platelet and endothelial cell binding/activation, activation of endothelial and inflammatory cells, inflammatory co-signal and circulating soluble spike protein variants following vaccination [1]. However, there are still other mechanisms that should be noted. First, the molecular mimicry phenomenon might exist and the cross-antibody reaction might be the cause of the problem [2]. Second, the thrombocytopenia might also be associated with increased blood viscosity after vaccination [3,4]. Finally, we should recognize of chance of other coincidence. For example, a dengue coinfection might be possible and can cause thrombocytopenia problem [5].

Authors contributions

RM 50% - 1a Substantial contributions to study conception and design 1b. Substantial contributions to acquisition of data 1c. Substantial contributions to analysis and interpretation of data 2. Drafting the article or revising it critically for important intellectual content 3. Final approval of the version of the article to be published.

VW 50% - 1a Substantial contributions to study conception and design 1b. Substantial contributions to acquisition of data 1c. Substantial contributions to analysis and interpretation of data 2. Drafting the

article or revising it critically for important intellectual content 3. Final approval of the version of the article to be published.

Declaration of competing interest

None.

References

- [1] Tsilingiris D, Vallianou NG, Karampela I, Dalamaga M. Vaccine induced thrombotic thrombocytopenia: the shady chapter of a success story. *Metabol Open* 2021 Sep;11: 100101.
- [2] McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. *J Autoimmun* 2021 Jul;121:102662.
- [3] Mungmunpantipantip R, Wiwanitkit V. Comment on: thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination. *Pediatr Blood Cancer* 2022 Jan;69(1):e29303.
- [4] Joob B, Wiwanitkit V. Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19. *Clin Appl Thromb Hemost* 2021 Jan-Dec;27: 10760296211020833.
- [5] Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. *Clin Appl Thromb Hemost* 2021 Jan-Dec;27: 10760296211047229.

Rujittika Mungmunpantipantip*
Bangkok, Thailand

Viroj Wiwanitkit
Dr DY Patil University, Pune, India

* Corresponding author.

E-mail address: rujittika@gmail.com (R. Mungmunpantipantip).

<https://doi.org/10.1016/j.metop.2022.100170>

Received 25 January 2022; Received in revised form 29 January 2022; Accepted 8 February 2022

Available online 10 February 2022

2589-9368/© 2022 The Authors.

Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).